The emergence of the biosimilar market represents an interesting opportunity for private equity firms in the global healthcare landscape. Here are the biggest deals from the last two years that suggest there is growing willingness outside of government funding to invest in biosimilar development — especially in emerging markets.
By Anna Rose Welch, chief editor, Biosimilar Development
In recent weeks, there have been several reports released on the current state of the U.S. biosimilar market — including IQVIA's Biosimilars in the U.S. 2020-2024. Overall, there were a few data points from this report that I thought were worth singling out and discussing a bit further.
White Paper |
By Omar A. Salman, Ph.D.,Pfizer CentreOne Contract Manufacturing
Sterile suspensions are particularly difficult to manufacture. This technical article covers factors for success, including particle size, vehicle formulation, and considerations for high-shear mixing.
Presented here are some tips to keep in mind when starting a cell sorting experiment. They will help you to maximize cell viability, separation, and isolation, and set you up for successful downstream applications.